• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 5. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130

Recent Advances in the Study of 7-Bromo-4-(trifluoromethyl)-1H-indole (CAS: 1260649-67-9) in Chemical Biology and Pharmaceutical Research

The compound 7-Bromo-4-(trifluoromethyl)-1H-indole (CAS: 1260649-67-9) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic molecule, characterized by its bromo and trifluoromethyl substituents, exhibits unique chemical properties that make it a valuable scaffold for drug discovery and development. Recent studies have explored its potential as a building block for the synthesis of novel bioactive compounds, particularly in the areas of oncology and infectious diseases.

One of the key areas of research involving 7-Bromo-4-(trifluoromethyl)-1H-indole is its role in the development of kinase inhibitors. Kinases are critical targets in cancer therapy, and the indole core of this compound provides a versatile platform for structural modifications. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of 7-Bromo-4-(trifluoromethyl)-1H-indole exhibited potent inhibitory activity against several tyrosine kinases, including EGFR and VEGFR2. The presence of the trifluoromethyl group was found to enhance binding affinity and metabolic stability, highlighting the compound's potential for further optimization.

In addition to its applications in oncology, 7-Bromo-4-(trifluoromethyl)-1H-indole has also been investigated for its antimicrobial properties. A recent preprint on bioRxiv reported that this compound, when incorporated into larger molecular frameworks, showed promising activity against drug-resistant bacterial strains such as MRSA. The bromo substituent was identified as a critical moiety for interacting with bacterial cell wall synthesis enzymes, suggesting a potential mechanism of action. These findings open new avenues for the development of next-generation antibiotics.

The synthetic accessibility of 7-Bromo-4-(trifluoromethyl)-1H-indole has also been a focus of recent research. A 2024 paper in Organic Letters described an efficient, one-pot synthesis method for this compound, achieving a yield of over 85% under mild reaction conditions. This advancement is particularly significant for scaling up production and facilitating further pharmacological studies. The method employs palladium-catalyzed cross-coupling reactions, which are compatible with a wide range of functional groups, making it highly versatile for medicinal chemistry applications.

Despite these promising developments, challenges remain in the clinical translation of 7-Bromo-4-(trifluoromethyl)-1H-indole-based therapeutics. Pharmacokinetic studies have indicated that while the compound exhibits favorable tissue distribution, its plasma stability may require further optimization. Ongoing research is exploring prodrug strategies and formulation approaches to address these limitations. Additionally, computational modeling studies are being conducted to predict the toxicity profiles of various derivatives, ensuring their safety for human use.

In conclusion, 7-Bromo-4-(trifluoromethyl)-1H-indole (CAS: 1260649-67-9) represents a highly promising scaffold in modern drug discovery. Its unique chemical properties, combined with recent synthetic and pharmacological advancements, position it as a valuable tool for addressing unmet medical needs. Future research directions may include the exploration of its applications in neurodegenerative diseases and autoimmune disorders, further expanding its therapeutic potential.

• 663193-19-9(Quinoline, 8-bromo-4-(trifluoromethyl)-)
• 663192-94-7(2,8-Dibromo-4-(trifluoromethyl)quinoline)
• 89446-67-3(4-Bromo-7-(trifluoromethyl)quinoline)
• 917251-92-4(8-Bromo-5-(trifluoromethyl)quinoline)
• 1059064-11-7(3-bromo-8-(trifluoromethyl)quinoline)
• 1198475-24-9(5-Bromo-6-(trifluoromethyl)-1H-indole)
• 875306-23-3(7-bromo-5-(trifluoromethyl)-1H-indole)
• 1000342-93-7(4-Bromo-6-(trifluoromethyl)-1H-indole)
• 630399-87-0(1H-Indole-3-ethanol, 7-bromo-4-(trifluoromethyl)-)
• 917251-86-6(8-Bromo-3-(trifluoromethyl)quinoline)